NARS2

Across TCGA pan-cancer cohorts, NARS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NARS2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher NARS2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NARS2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where NARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.870	0.454	<.001	47	view →
LUAD	DFS	Median	II,III,IV	0.960	0.754	.004	9	view →
PDAC	OS	Median	III,IV	1.000	0.537	.008	8	view →
UCEC	OS	Median	All	0.918	0.981	.043	6	view →
HNSC	DFS	Quartile	II,III,IV	0.866	0.973	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NARS2–LSCC (DFS)

Open the LSCC breakdown →